Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elexacaftor/tezacaftor/ivacaftor with tacrolimus interaction study in transplanted adults with cystic fibrosis
NL-OMON52229Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Feb 2022
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of elexacaftor, tezacaftor, ivacaftor and tacrolimus in cystic fibrosis (CF), sponsored by HagaZiekenhuis. Primary endpoints: Tacrolimus pharmacokinetic parameters with and without elexacaftor/tezacaftor/ivacaftor, Change in tacrolimus pharmacokinetic parameters per individual and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftortacrolimus
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON52229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52229.